1
|
Olennikov DN, Kashchenko NI. Gentianopsis metabolites and bioactivity: HPLC-PDA-ESI-tQ-MS/MS profiles, HPLC-UV quantification of Gentianopsis komarovii and Gentianopsis stricta, and choleretic potential. Nat Prod Res 2024; 38:158-163. [PMID: 35921543 DOI: 10.1080/14786419.2022.2107640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 07/26/2022] [Indexed: 11/09/2022]
Abstract
Gentianopsis is a small gentianaceous genus with a known ethnopharmacological focus as hepatoprotectors containing two underestimated species that are scientifically unexplored: Gentianopsis komarovii (Grossh.) Toyok., which is typical of the Far East, and Gentianopsis stricta (Klotzsch) Ikonn., which is grown in Central Asia. Application of the HPLC-PDA-ESI-tQ-MS/MS technique led to the identification of 28 compounds, such as iridoid glycosides, flavones and xanthones, with loganic acid, sweroside, loganin, secologanin, isoorientin-7-O-glucoside, luteolin-7-O-gentiobioside, chrysoeriol-7-O-glucoside and acacetin-7-O-glucoside being found in the genus for the first time. The extracts of G. komarovii and G. stricta demonstrated choleretic potential, strengthening the bile flow and the total content of bile acids, bilirubin and cholesterol in the bile. The most pronounced effects were observed for luteolin-7-O-glucoside and gentiabavaroside (gentiacaulein-1-O-primveroside), establishing them as the principle choleretics of both herbs. Based on the results, G. komarovii, G. stricta and some phenolic metabolites are prospective new choleretic drugs.
Collapse
Affiliation(s)
- Daniil N Olennikov
- Institute of General and Experimental Biology, Laboratory of Medical and Biological Research, Ulan-Ude, Russia
| | - Nina I Kashchenko
- Institute of General and Experimental Biology, Laboratory of Medical and Biological Research, Ulan-Ude, Russia
| |
Collapse
|
2
|
Huang PQ, Kang KW, Huang DY, Zhao CL, Zheng H, Luo YX, Wen Y, Zou MF, Li DL, Wu RH, Tian YC, Tian Y, Zhang WH, Jin JW, Yin S, Gan LS. Lignan glucosides from Gentiana macrophylla with potential anti-arthritis and hepatoprotective activities. PHYTOCHEMISTRY 2024; 217:113920. [PMID: 37951561 DOI: 10.1016/j.phytochem.2023.113920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/04/2023] [Accepted: 11/07/2023] [Indexed: 11/14/2023]
Abstract
Ten lignans, including six previously undescribed phenolic ester glycosyl lignans (1-6), were isolated from a well-known traditional Chinese medicine, Qin-Jiao, which is the dry root of Gentiana macrophylla Pall. (Gentianaceae). Their structures were determined by spectroscopic and chemical methods, especially 2D NMR techniques. Quantum chemical calculations of theoretical ECD spectra allowed the determination of their absolute configurations. Refer to its traditional applications for the treatment of rheumatic arthralgia and hepatopathy, these compounds were evaluated on a TNF-α induced MH7A human synoviocyte inflammation model and a D-GalN induced AML12 hepatocyte injury model. Compounds 1, 2, 5, and 6 significantly reduced the release of proinflammatory cytokine IL-1β in MH7A cells at 15 μM and they also could strongly protect AML12 cells against D-GalN injury at 30 μM. Flow cytometry and Western blot analysis showed that compound 5 ameliorated D-GalN induced AML12 cell apoptosis by upregulating the expression of anti-apoptotic Bcl-2 protein and down-regulating the expression of pro-apoptotic Bax protein.
Collapse
Affiliation(s)
- Pei-Qi Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Kai-Wen Kang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Dan-Yu Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Chun-Lin Zhao
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Hao Zheng
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yong-Xin Luo
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yan Wen
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Ming-Feng Zou
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Dong-Li Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Ri-Hui Wu
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yun-Cai Tian
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Yong Tian
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Wen-Huan Zhang
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Jing-Wei Jin
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China.
| | - Sheng Yin
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China.
| | - Li-She Gan
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
| |
Collapse
|
3
|
Huang PQ, Luo YX, Zhang YJ, Li ZX, Wen Y, Zhang K, Li DL, Jin JW, Wu RH, Gan LS. Terpenoid Glucosides from Gentiana macrophylla That Attenuate TNF-α Induced Pulmonary Inflammation in A549 Cells. Molecules 2023; 28:6613. [PMID: 37764389 PMCID: PMC10535684 DOI: 10.3390/molecules28186613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 07/28/2023] [Accepted: 08/10/2023] [Indexed: 09/29/2023] Open
Abstract
Four previously undescribed terpenoid glucosides, including one sesquiterpenoid di-glucoside (1), two new iridoid glucosides (2, 3), and a new triterpenoid tri-glucoside (4), were isolated from a 70% ethanol extract of the root of Gentiana macrophylla (Gentianaceae), along with eight known terpenoids. Their structures were determined by spectroscopic techniques, including 1D, 2D NMR, and HRMS (ESI), as well as chemical methods. The absolute configuration of compound 1 was determined by quantum chemical calculation of its theoretical electronic circular dichroism (ECD) spectrum. The sugar moieties of all the new compounds were confirmed to be D-glucose by GC analysis after acid hydrolysis and acetylation. Anti-pulmonary inflammation activity of the iridoids were evaluated on a TNF-α induced inflammation model in A549 cells. Compound 2 could significantly alleviate the release of proinflammatory cytokines IL-1β and IL-8 and increase the expression of anti-inflammatory cytokine IL-10.
Collapse
Affiliation(s)
- Pei-Qi Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yong-Xin Luo
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yu-Jia Zhang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Zhi-Xuan Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yan Wen
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Kun Zhang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Dong-Li Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Jing-Wei Jin
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Ri-Hui Wu
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Li-She Gan
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China
| |
Collapse
|